Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Woodford Debacle Is A Test Of UK Biotech’s Resilience

As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.

 

United Kingdom Financing

One Patient, Many Questions: Milasen ‘N of 1’ Trial Provides Early Template For Individualized Genomic Medicine

Rapid development of patient-customized oligonucleotide at Boston Children’s Hospital suggests promise and hazards of new drug development model.

Drug Approval Standards Rare Diseases

From Rare To Real: Pharma Urged To Act As China Preps New Rare Conditions List

Chinese regulatory agency working around the clock in preparation to release another official list of rare diseases, and a push to launch more innovative orphan drugs is underway. But this time pharma firms need to be more proactive, noted an NMPA official.

China Rare Diseases

US FDA Reassures ALS Patients In Final Development Guidance

ALS advocates succeed in getting the FDA to soften its stance on use of randomized, placebo-controlled trials for drug development; final guidance also encourages patient-reported outcomes.

Neurology Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register